Importance & Scope:
Scope: Cell & Gene Therapy
Plant Stem Cells: Human Therapeutics
Cellular & Molecular Biology
Importance: Conference on Cell & Gene Therapy is a much celebrated conference which basically deals with the latest research and developments in the sphere of Cell and molecular biology. This Conference will provide a perfect platform to all the International mix of leading Research Scholars, and Scientists achieved eminence in their field of study, research academicians from the universities and research institutions, industrial research professionals and business associates along with Ph.D. Students to come and inform all the attendees about the latest scientific advancements on the respective sphere.
The United Kingdom of Great Britain and Northern Ireland, commonly known as the United Kingdom (United Kingdom) or Britain is a sovereign state located off the north-western coast of continental Europe. The country includes the island of Great Britain (a term sometimes loosely applied to the whole state), the north-eastern part of the island of Ireland, and many smaller islands.
The total area of the United Kingdom is approximately 243,610 square kilometres (94,060 sq mi). The country occupies the major part of the British Isles archipelago and includes the island of Great Britain, the north-eastern one-sixth of the island of Ireland and some smaller surrounding islands. The United Kingdom has a temperate climate, with plentiful rainfall all year round.
England and Scotland were leading centre of the Scientific Revolution from the 17th century and the United Kingdom led the Industrial Revolution from the 18th century, and has continued to produce scientists and engineers credited with important advances. Scientific research and development remains important in British universities, with many establishing science parks to facilitate production and co-operation with industry. Between 2004 and 2008 the United Kingdom produced 7% of the world’s scientific research papers and had an 8% share of scientific citations, the third and second highest in the world.
· Cell and Gene Therapy: Potential Applications
· Plant Stem Cell Rejuvenation
· Plant Stem Cells: Human Therapeutics
· Stem Cell Therapies
· Cellular Therapies
· Advanced Gene Therapeutics
· Molecular basis of epigenetics
· Cancer Therapies
· Bioengineering Therapeutics
Topics to be mainly focused
· University contacts
· Associations Involvement for collaborations
· Companies related to conference theme
· Encouraging active student participations in groups
· Qualitative indexing and press releases
· Through promotions in social network sites
· Blog posts
· Advertisements/attending in competitive conferences for mutual promotions
Why to attend???
MEET YOUR TARGET SCIENTISTS, PROFESSORS ACHIEVED EMINENCE IN THEIR FIELD OF STUDY with members from around the world focused on learning about Gene Therapy, this is your single best opportunity to reach the largest assemblage of participants from all over the world. Conduct demonstrations, distribute information, meet with current and potential scientific discoveries, make a splash with a new product line, and receive name recognition at this 3-day event. World-renowned speakers, the most recent techniques, tactics, and the newest updates in Gene Therapy fields are hallmarks of this conference.
Be Part of it!
· This conference focusing on all the major aspects in the fields of Gene Therapy as well as Cell therapy
· It would be beneficial for all the students who ever willing to enter into corporate worlds targeting to the respective fields
· This Meeting strategic astuteness is to be an event for bringing together Scientists, Physicians, International mix of leading Universities, Cell and Gene Therapy Institutions to transform the practice of medicine by incorporating the use of genetic and cellular therapies to control and cure human disease.
Members Associated with Gene Therapy:
Figure: Member Associated
Societies Associated with Gene Therapy
· British Society and Gene and Cell Therapy
· American Society of Gene and Cell Therapy (ASGCT)
· Australasian Gene Therapy Society (AGTS)
· Austrian Network for Gene Therapy
· British Society of Gene Therapy (BSGT)
· European Society of Gene and Cell Therapy (ESGCT)
· Finnish Gene Therapy Society (FGTS)
· German Gene Therapy Society (DGGT)
· International Society for Cancer Gene Therapy (ISCGT)
· Irish Society for Gene & Cell Therapy (ISGCT)
· Israeli Society of Gene & Cell Therapy (ISGCT)
· Japan Society of Gene Therapy (JSGT)
· Korean Society of Gene and Cell Therapy (KSGCT)
· Netherlands Society of Gene and Cell Therapy (NVGCT)
· Société Francophone de ThérapieCellulaire et Génique (SFTCG)
· Spanish Society of Gene and Cell Therapy (SETGyC)
· Swedish Society for Gene and Cell Therapy (SSGCT)
· Turkish Society of Gene & Cell Therapy (TSGCT)
Industries Associated with Gene Therapy
Top Research Institutes of Gene Therapy Globally
Figure: List of Research Institutes
Market Value on Gene Therapy
In the UK limbal stem cell therapy costs an average of £3,000/subject whereas a conventional corneal transplant is billed at £6,000. The latter would also require more significant aftercare to reduce and GvHD, thus an autologous limbal stem cell therapy has potential to be doubly economical. Likewise an allogeneic bone marrow transplant for a patient with a primary immunodeficiency costs typically £250,000 and upwards, given the cost of inpatient stay, drugs and frequency of complications such as GvHD. In contrast, manufacture of autologous gene modified CD34 + cells can be achieved for approx. £15,000–30,000. The additional follow-up costs of gene therapy treatment for primary immune deficiencies are likely to be significantly less given that the length of hospital stay, long-term prophylactic medication requirements and other post-therapy complications are considerably reduced compared to conventional BMT. GMP manufacturing costs for the ATMPs currently in clinical trials at Great Ormond Street Hospital are broken down into vector procurement costs of £5,000–15,000 per trial participant, largely dependent on the individual's age/body mass; plus aseptic manufacture costs typically £10,000 ± £3,000 per patient per product, the range being dependent upon the number of days of culture required and the complexity of the gene transfer process.
Figure: Market Value
Products manufactured by the industry related Gene Therapy and its market Value.
· The global market for products to treat genetic disorders was worth $12.8 billion in 2009 and is estimated to reach $17.3 billion by 2014, a compound annual growth rate (CAGR) of more than 6%.
· The gene mutation disorder segment is the largest in terms of sales and is considered to be a more successful area for development activity. This segment generated $11.3 billion in 2009 and is projected to increase at a compound annual growth rate (CAGR) of 6.5% to reach $15.6 billion in 2014.
· The chromosomal disorders segment was valued at $1.5 billion in 2009. By 2014, this market is expected to be worth $1.8 billion, a compound annual growth rate (CAGR) of 3.7%.
Figure: Products Manufacture Value